{"paper_id":"e1de845e-78ba-4856-ad66-2f045e28b27d","body_text":"/u.sc/n.sc/i.sc/v.sc/e.sc/r.sc/s.sc/i.sc/t.sc/y.sc /o.sc/f.sc /c.sc/o.sc/p.sc/e.sc/n.sc/h.sc/a.sc/g.sc/e.sc/n.sc \nKøbenhavns Universitet\nHysterectomy and risk of epithelial ovarian cancer by histologic type, endometriosis,\nand menopausal hormone therapy\nRing, Linea Landgrebe; Baandrup, Louise; Zheng, Guoqiao; Gottschau, Mathilde;\nDehlendorff, Christian; Mellemkjær, Lene; Kjaer, Susanne K.\nPublished in:\nCancer Epidemiology\nDOI:\n10.1016/j.canep.2023.102359\nPublication date:\n2023\nDocument version\nEarly version, also known as pre-print\nDocument license:\nUnspecified\nCitation for published version (APA):\nRing, L. L., Baandrup, L., Zheng, G., Gottschau, M., Dehlendorff, C., Mellemkjær, L., & Kjaer, S. K. (2023).\nHysterectomy and risk of epithelial ovarian cancer by histologic type, endometriosis, and menopausal hormone\ntherapy. Cancer Epidemiology, 84, Article 102359. https://doi.org/10.1016/j.canep.2023.102359\nDownload date: 18. Nov. 2026\n\nPage 1/15\nHysterectomy and risk of epithelial ovarian cancer\nby histologic type, endometriosis, and menopausal\nhormone therapy\nLinea Landgrebe Ring \nDanish Cancer Society: Kraeftens Bekaempelse https://orcid.org/0000-0001-7149-8908\nLouise Baandrup \nMathilde Gottschau \nChristian Dehlendorff \nLene Mellemkjær \nSusanne K. Kjaer \nhttps://orcid.org/0000-0002-8347-1398\nResearch Article\nKeywords: Epithelial ovarian cancer, hysterectomy, histological type, endometriosis, menopausal\nhormone therapy\nPosted Date: November 1st, 2022\nDOI: https://doi.org/10.21203/rs.3.rs-2173859/v1\nLicense:   This work is licensed under a Creative Commons Attribution 4.0 International License.  \nRead Full License\nVersion of Record: A version of this preprint was published at Cancer Epidemiology on June 1st, 2023.\nSee the published version at https://doi.org/10.1016/j.canep.2023.102359.\n\nPage 2/15\nAbstract\nPurpose\nThis nationwide, register-based case-control study investigated the association between hysterectomy\nand risk of epithelial ovarian cancer according to histology and by history of endometriosis and MHT\nuse.\nMethods\nFrom the Danish Cancer Registry, all women registered with epithelial ovarian cancer during 1998 ‒ 2016\nwere identied (n = 6,738). Each case was sex- and age-matched to 15 population controls using risk-set\nsampling. Information on previous hysterectomy on benign indication and potential confounders was\nretrieved from nationwide registers. Conditional logistic regression was used to calculate odds ratios\n(ORs) with 95% condence intervals (CIs) for the association between hysterectomy and ovarian cancer\naccording to histology, endometriosis, and use of MHT.\nResults\nHysterectomy was not associated with risk of epithelial ovarian cancer overall (OR = 0.97; 95% CI 0.88 ‒\n1.06) but was associated with reduced risk of clear cell ovarian cancer (OR = 0.47; 95% CI 0.28 ‒ 0.78). In\nstratied analyses, decreased ORs associated with hysterectomy were seen in women with\nendometriosis (OR = 0.73; 95% CI 0.50 ‒ 1.09) and in non-users of MHT (OR = 0.87; 95% CI 0.76 ‒ 1.00).\nConclusion\nHysterectomy was not associated with epithelial ovarian cancer overall but with reduced risk of clear cell\novarian cancer. Our ndings may suggest a reduced risk of ovarian cancer after hysterectomy in women\nwith endometriosis and in MHT non-users, but the statistical precision of our results did not allow rm\nconclusions.\nwhat Does This Study Adds To The Clinical Work\nWe found an inverse association between hysterectomy and the risk of clear cell ovarian cancer, and a\npotential protection against ovarian cancer in women with endometriosis and in non-users of\nmenopausal hormone-therapy. \nIntroduction\n\nPage 3/15\nWorldwide, ovarian cancer is the eighth most common cancer in women with an age-standardized\nincidence rate of 6.6 cases per 100,000 person-years [1]. Approximately 95% of ovarian cancers are of\nepithelial origin and are primarily classied into ve main types; high- and low-grade serous,\nendometrioid, clear cell, and mucinous ovarian cancer [2]. High-grade serous carcinoma is the most\ncommon histological type accounting for approximately 70% of ovarian carcinomas [2].\nIt has been suggested that hysterectomy protects against ovarian cancer by blocking transfer of\ncarcinogenic agents, and retrograde menstruation or endometriosis travelling through the female genital\ntract [3–5]. A number of studies have investigated the association between hysterectomy and risk of\novarian cancer with inconsistent ndings [4–15]. A meta-analysis observed a time-dependent trend in\nndings and pointed out that one explanation could be changes over time in use of menopausal\nhormone therapy (MHT) [13]. MHT is known to increase the risk of ovarian cancer moderately [16, 17],\nand is more commonly used among hysterectomized women [18], which might explain why a few recent\nobservational studies have reported that the association between hysterectomy and ovarian cancer risk\ndiffers by use of MHT [8–10]. Other studies have reported that the association between hysterectomy\nand ovarian cancer varies by tumor histology [5, 6, 9, 12], and history of endometriosis [6, 10, 14].\nConcomitant removal of the fallopian tubes and/or ovaries at time of hysterectomy are also important\nfactors to consider. Recent research has revealed that the precursor lesion of high-grade serous\ncarcinoma originates in the fallopian tube as serous tubal intraepithelial carcinoma lesions [19], and that\nbilateral salpingectomy therefore reduces the risk of ovarian cancer [3, 7].\nClarication of the impact of hysterectomy on the risk of ovarian cancer may elucidate the pathogenesis\nof the disease but it is also important from a clinical point of view to determine whether the procedure\nprotects against ovarian cancer, and identify potential target groups who benet the most.\nThe aim of this nationwide register-based case-control study is to evaluate the association between\nhysterectomy on benign indication and the risk of ovarian cancer. Our analyses are stratied by\nhistologic subtype of ovarian cancer and investigate whether endometriosis and MHT may be effect\nmodiers for the association between hysterectomy and the risk of ovarian cancer.\nMethods\nThis nationwide, register-based case-control study has previously been described in detail [3], and has\nsince been updated with four additional years. In Denmark, the Civil Registration System assigns all\nDanish citizens a personal identication number, which enables accurate linkage between the different\nregisters. The register also contains information on dates of death, and migration to and from Denmark\n[20].\nStudy population\nCases were identied in the Danish Cancer Registry, which contains information on cancer diagnoses in\nDenmark since 1943 and with mandatory reporting of new cancer cases since 1987 [21]. Since 2004,\n\nPage 4/15\ncancer cases have been registered using the 10th revision of the International Classication of Diseases\n(ICD-10) and the 3rd revision of the International Classication of Diseases for Oncology (ICD-O-3), and\ncodes for cancer cases registered during 1978 ‒ 2003 have been converted to ICD-10 and ICD-O-3. Cases\nwere identied in the Cancer Registry by ICD-10 DC56. We required that cases were aged 40 ‒ 79 years at\nthe index date, dened as the date of diagnosis, without previous cancer, and with a rst diagnosis of\nhistologically veried epithelial ovarian cancer during 1998 ‒ 2016. Ovarian cancer cases were classied\naccording to the ICD-O-3 morphology code into serous, endometrioid, clear cell, mucinous and other\n(Supplementary Table S1). Information on grade was not available.\nEach case was matched by month and year of birth to 15 control women identied in the Civil\nRegistration System using risk set sampling. Controls were not allowed to have a history of bilateral\noophorectomy/salpingo-oophorectomy or cancer (except non-melanoma skin cancer) at the time the\ncorresponding case was diagnosed, i.e., index date. Women were eligible as controls before becoming\ncases.\nInformation on exposure\nInformation on hysterectomy up until one year prior to index date was retrieved from the Danish National\nPatient Register, which has registered all diagnoses and surgical procedures performed during\nhospitalizations since 1977, and during outpatient visits since 1995 [22]. From 1977 to 1993, all\ndiagnoses are coded according to ICD-8, and from 1994 diagnoses are coded according to ICD-10. All\nsurgical procedures are classied according to the Danish Classication of Surgical Procedures up until\nthe end of 1995, and afterwards according to the Nordic Classication of Surgical Procedures.\nInformation on covariates\nInformation on use of oral contraceptives and MHT was obtained from the Danish National Prescription\nRegistry, where individual-level information on all prescription drugs dispensed at pharmacies in\nDenmark since 1995 are registered [23], and classied by the Anatomical Therapeutic Chemical Index\n[24]. From the Danish National Patient Register, information since 1977 on endometriosis, tubal ligation,\nand other gynecological surgical procedures including salpingectomies and oophorectomies up until one\nyear prior to index date was obtained. Parity was derived from the Danish Fertility Database, which\ncontains information on reproductive variables for all women aged 13 ‒ 49 years in Denmark from 1980\nand onwards [25].\nStatistical analyses\nWe used conditional logistic regression to calculate age-matched and multivariable adjusted odds ratios\n(ORs) and 95% condence intervals (CIs) for the association between hysterectomy and risk of epithelial\novarian cancer overall and stratied according to histologic subtype. Potential confounders were\nselected a priori based on evidence of risk factors for ovarian cancer and availability in the registers. The\nmodel was adjusted for age (by design), parity, endometriosis, tubal ligation, other gynecological surgical\n\nPage 5/15\nprocedures (tubal ligation, unilateral/bilateral salpingectomy, unilateral oophorectomy, and unilateral\nsalpingo-oophorectomy), and use of oral contraceptives and MHT.\nTo investigate effect modication by endometriosis and MHT use, we performed stratied analysis using\nlogistic regression without the matching, but with adjustment for the matching factors (age and calendar\nyear). All analyses were performed using the statistical software R version 4.1.0.\nUse of register data for this study was approved by the Danish National Board of Health Data (FSEID-\n4295). In agreement with the General Data Protection Regulation, the present study is registered in the\nDanish Cancer Society’s internal list of projects dealing with personalized data (journal number: 2019-\nDCRC-0054). All data related to the study are stored at the Danish Cancer Society Research Center’s\nproject database at Statistics Denmark (project number 704327), and the Danish Cancer Society is\nresponsible for the data stored at this project database. The data that support the information of this\nmanuscript were accessed remotely on a secure platform at Statistics Denmark (www.dst.dk).\nAccording to Danish laws and regulations, individual-level sensitive data can only be made available for\nresearchers who full legal requirements for accessing personal sensitive data.\nResults\nThe study population included 6,738 women with epithelial ovarian cancer and 101,070 matching\ncontrols. The majority of cases were 60 ‒ 79 years old at diagnosis and the most common histologic type\nof tumor was serous (58.7%) (Table 1). Hysterectomy was reported in 588 (8.7%) cases and in 9,289\n(9.2%) controls. Cases (18.1%) were more likely to be nulliparous compared with controls (12.7%).\nEndometriosis was diagnosed in 130 (1.9%) cases and in 1,665 (1.6%) controls. Finally, ever use of MHT\nwas slightly more common among cases (35.6%) compared with controls (33.2%).\n\nPage 6/15\nTable 1\n Characteristics of women with epithelial ovarian cancer and matching controls\n  Cases Controls\n(n = 101,070)(n = 6,738)\nCharacteristics n % n %\nHistology        \nSerous 3,953 (58.7) —  \nMucinous 565 (8.4) —  \nEndometrioid 596 (8.8) —  \nClear cell 328 (4.9) —  \nOther 1,296 (19.2) —  \nAge at diagnosis / index date (years)        \n40–49 794 (11.8) 11,910 (11.8)\n50–59 1,707 (25.3) 25,605 (25.3)\n60–69 2,270 (33.7) 34,050 (33.7)\n70–79 1,967 (29.2) 29,505 (29.2)\nHysterectomy        \nNo 6,150 (91.3) 91,781 (90.8)\nYes 588 (8.7) 9,289 (9.2)\nAge at hysterectomy (years)      \nNo hysterectomy 6,150 (91.3) 91,781 (90.8)\n<50 459 (6.8) 7,036 (7.0)\n≥ 50 129 (1.9) 2,253 (2.2)\nParity        \nNulliparous 1,218 (18.1) 12,866 (12.7)\nOne 1,311 (19.5) 17,047 (16.9)\nTwo 2,631 (39.0) 42,629 (42.2)\nThree or more 1,578 (23.4) 28,528 (28.2)\nEndometriosis        \nNo 6,608 (98.1) 99,405 (98.4)\n\nPage 7/15\n  Cases Controls\n(n = 101,070)(n = 6,738)\nYes 130 (1.9) 1,665 (1.6)\nOral contraceptives      \nNo 6,309 (93.6) 90,667 (89.7)\nYes 429 (6.4) 10,403 (10.3)\nMenopausal hormone therapy    \nNo (< 2 prescriptions) 4,342 (64.4) 67,467 (66.8)\nYes (> 2 prescriptions) 2,396 (35.6) 33,603 (33.2)\nTubal ligation        \nNo 6,411 (95.1) 94,775 (93.8)\nYes 327 (4.9) 6,295 (6.2)\nOther gynecological surgical proceduresa        \nNo 6,563 (97.4) 96,969 (95.9)\nYes 175 (2.6) 4,101 (4.1)\nHysterectomy was not associated with the overall risk of epithelial ovarian cancer (OR = 0.97; 95% CI\n0.88 ‒ 1.06) (Table 2). When the analysis was stratied according to tumor histology, we observed a\nsignicantly reduced risk of clear cell ovarian cancer after hysterectomy (OR = 0.47; 95% CI 0.28 ‒ 0.78).\nThe OR for mucinous ovarian cancer was decreased (OR = 0.80; 95% CI 0.56 ‒ 1.14), whereas an elevated\nOR was observed for endometrioid ovarian cancer (OR = 1.29; 95% CI 0.97 ‒ 1.72). Finally, hysterectomy\nwas associated with neutral ORs for serous (OR = 1.00; 95% CI 0.89 ‒ 1.13) and other epithelial ovarian\ncancers (OR = 0.96; 95% CI 0.76 ‒ 1.20).\n\nPage 8/15\nTable 2\nHysterectomy and risk of epithelial ovarian cancer stratied according to histologic subtype\n  Cases   Controls   Age-adjusted   Adjusteda\nHistologicsubtype N (%)   N (%)   OR 95% CI   OR 95% CI\nAll epithelial                      \nNohysterectomy 6,150 (91.3)   91,781 (90.8)   Ref.   Ref.\nHysterectomy 588 (8.7)   9,289 (9.2)   0.94 (0.86 ‒1.03)   0.97 (0.88 ‒1.06)\nSerous                      \nNohysterectomy 3,585 (90.7)   53,677 (90.5)   Ref.   Ref.\nHysterectomy 368 (9.3)   5,618 (9.5)   0.98 (0.88 ‒1.10)   1.00 (0.89 ‒1.13)\nMucinous                      \nNohysterectomy 529 (93.6)   7,715 (91.0)   Ref.   Ref.\nHysterectomy 36 (6.4)   760 (9.0)   0.69 (0.49 ‒0.97)   0.80 (0.56 ‒1.14)\nEndometrioid                     \nNohysterectomy 531 (89.1)   8,156 (91.2)   Ref.   Ref.\nHysterectomy 65 (10.9)   784 (8.8)   1.28 (0.98 ‒1.67)   1.29 (0.97 ‒1.72)\nClear cell                      \nNohysterectomy 309 (94.2)   4,466 (90.8)   Ref.   Ref.\nHysterectomy 19 (5.8)   454 (9.2)   0.60 (0.37 ‒0.97)   0.47 (0.28 ‒0.78)\nOther                      \nNohysterectomy 1,196 (92.3)   17,767 (91.4)   Ref.   Ref.\nHysterectomy 100 (7.7)   1,673 (8.6)   0.89 (0.72 ‒1.10)   0.96 (0.76 ‒1.20)\nAbbreviations: OR, Odds ratio; CI, Condence interval; Ref., Reference\n\nPage 9/15\n  Cases   Controls   Age-adjusted   Adjusteda\naAdjusted for age (by design), calendar year (by design), parity (categorical), tubal ligation,endometriosis, other gynaecological surgical procedures, oral contraceptive use, and use ofmenopausal hormone therapy.\nTable 3 presents the analysis stratied according to occurrence of endometriosis. In women with a\nprevious diagnosis of endometriosis, hysterectomy was associated with a reduced OR for ovarian cancer\n(OR = 0.73; 95% CI 0.50 ‒ 1.09), whereas the association between hysterectomy and ovarian cancer in\npatients without a diagnosis of endometriosis was close to unity (OR = 0.99; 95% CI 0.90 ‒ 1.08).\nTable 3\nHysterectomy and risk of epithelial ovarian cancer by history of endometriosis\n  Age-adjusted\nOR (95% CI)\n  Adjusteda\nOR (95% CI)\nNo endometriosis      \nNo hysterectomy Ref.   Ref.\nHysterectomy 1.04 (0.94 ‒ 1.14)   0.99 (0.90 ‒ 1.08)\nEndometriosis      \nNo hysterectomy Ref.   Ref.\nHysterectomy 0.75 (0.51 ‒ 1.12)   0.73 (0.50 ‒ 1.09)\nAbbreviations: OR, Odds ratio; CI, Condence interval; Ref., Reference\naAdjusted for age, calendar year, parity (categorical), tubal ligation, other gynaecological surgicalprocedures, oral contraceptive use and use of menopausal hormone therapy.\nFinally, we examined the effect of hysterectomy stratied according to use of MHT. The ORs for the\nassociation between hysterectomy and ovarian cancer were 0.87 (95% CI 0.76 ‒ 1.00) in women who\nnever used MHT and 1.05 (95% CI 0.93 ‒ 1.19) in women who had redeemed minimum two prescriptions\nof MHT before index date (Table 4).\n\nPage 10/15\nTable 4\nHysterectomy and risk of epithelial ovarian cancer by ever use of menopausal hormone therapy (MHT)\n  Age-adjusted\nOR (95% CI)\n  Adjusteda\nOR (95% CI)\nNon-use of MHT      \nNo hysterectomy Ref.   Ref.\nHysterectomy 0.90 (0.78 ‒ 1.03)   0.87 (0.76 ‒ 1.00)\nEver-use of MHT      \nNo hysterectomy Ref.   Ref.\nHysterectomy 1.08 (0.95 ‒ 1.22)   1.05 (0.93 ‒ 1.19)\nOR: Odds ratio; CI: Condence interval; Ref.: Reference\naAdjusted for age, calendar year, parity (categorical), tubal ligation, other gynaecological surgicalprocedures, and use of oral contraceptives.\nDiscussion\nIn this study hysterectomy was not associated with the risk of epithelial ovarian cancer overall but\nseemed to reduce risk of the clear cell type. In women with endometriosis and in women not using MHT,\nreduced odds for ovarian cancer after hysterectomy were observed.\nIn line with our ndings, recent studies have found no association between hysterectomy and risk of\novarian cancer overall [6, 10, 15], and a meta-analysis reported a pooled OR of 0.97 (95% CI: 0.83–1.12)\nbased on data from 18 case-control studies published between 2000 and 2017 [5]. In contrast, data from\ntwo earlier meta-analyses published in 2012 [4], and 2013 [13], respectively, suggested that hysterectomy\nwas associated with a lower risk of ovarian cancer. Both meta-analyses reported signicant\nheterogeneity between the included studies primarily explained by median year of ovarian cancer\ndiagnosis, where studies published before 2000 indicated a lower risk of ovarian cancer following\nhysterectomy, whereas studies published after 2000 did not. The authors speculated that the temporal\nchange in the association between hysterectomy and ovarian cancer risk could in part be attributed to\nincreasing use of MHT over calendar time in hysterectomized women [13].\nMHT is more commonly prescribed to hysterectomized women than to non-hysterectomized women\n[18], and is associated with a moderately increased ovarian cancer risk [16, 17]. In accordance, a recent\nstudy from the Ovarian Cancer Association Consortium (OCAC) found that adjustment for duration of\nMHT use affected the association between hysterectomy and ovarian cancer risk markedly [10]. A case-\ncontrol study including 614 African-American women with ovarian cancer reported that hysterectomy\ndecreased the risk of epithelial ovarian cancer (OR = 0.65, 95% CI: 0.46 ‒ 0.92) in never users of estrogen-\n\nPage 11/15\nonly MHT, whereas increased odds was observed among users [8]. Moreover, data from the Nurses’\nHealth Study also showed that hysterectomy was associated with decreased odds for ovarian cancer\nonly in women who had never used MHT (hazard ratio (HR) = 0.81, 95% CI: 0.54 ‒ 1.20) [9], which is in line\nwith our ndings.\nOvarian cancer is a heterogeneous disease and the etiology of the different subtypes may differ.\nTherefore, it is also suggested that the association between hysterectomy and ovarian cancer may vary\naccording to the histological types of epithelial ovarian cancer [5, 6, 9]. Endometrioid and clear cell types\nare strongly associated with endometriosis [26]. By preventing menstruation or endometriosis from\nretrograde transport through the female genital tract, hysterectomy may protect primarily against those\ntypes of ovarian cancer. A meta-analysis pooling data from four case-control studies with information on\ntumor histology reported that hysterectomy was associated with a statistically signicant risk reduction\nfor endometrioid/clear cell ovarian cancer (OR = 0.70, 95% CI: 0.51 ‒ 0.94) [5]. The OR for mucinous\novarian cancer was reduced but statistically not signicant and there was no association between\nhysterectomy and serous ovarian cancer [5]. Other studies not included in the meta-analysis by Huo et al.\n[5] have also reported that hysterectomy protected against clear cell ovarian cancer [12] or that risk\nestimates for endometrioid and/or clear cell ovarian cancer pointed in the protective direction without\nstatistical signicance [6, 9, 12]. Risk estimates for mucinous ovarian cancer are also reported\nstatistically non-signicantly decreased in several studies [6, 9, 12], whereas a null-association with\nserous ovarian cancer is most often observed [6, 9, 12]. Our results are consistent with the majority of\nprevious recent studies, as we also found that hysterectomy was not associated with serous ovarian\ncancer but protected against clear cell ovarian cancer. However, our data showed increased odds for\nendometrioid ovarian cancer after hysterectomy. We have no denite explanation for this nding but\nmisclassication may have played a role. Cases in our study go back to 1998 and some of the tumors\nthat were diagnosed as endometrioid ovarian cancers may have been classied as high-grade serous\ncarcinomas today based on their immunoprole [27]. The association between hysterectomy and\nendometrioid ovarian cancer may also be affected by unmeasured confounding. Although our study was\nbased on high-quality nationwide registers, registration of potential confounders such as endometriosis\nmay not be complete.\nOur ndings in stratied analysis showing reduced odds for ovarian cancer after hysterectomy in women\nwith endometriosis is compatible with reports from previous studies [6, 10, 14]. One study with pooled\ninformation from four US population-based case-control studies reported that hysterectomy was\nassociated with statistically non-signicantly decreased odds for ovarian cancer (OR = 0.69, 95% CI:\n0.38 ‒ 1.24) in women with endometriosis, whereas this was not found in women without endometriosis\n(OR = 1.02, 95% CI: 0.86 ‒ 1.23) [14]. In addition, an Australian register-based cohort study reported\nsubstantially decreased risk of ovarian cancer (HR = 0.17, 95% CI: 0.12 ‒ 0.24) after hysterectomy in\nwomen with endometriosis [6], and OCAC data also showed that hysterectomy statistically signicantly\nreduced the risk of ovarian cancer in women with endometriosis (OR = 0.69, 95% CI 0.48 ‒ 0.99) [10].\nAlthough hysterectomy, as previously discussed, may prevent retrograde transport of endometriosis, the\n\nPage 12/15\nobserved protective effect of hysterectomy on ovarian cancer risk among women with endometriosis\nmay also be explained by removal of endometriotic lesions at the time of hysterectomy.\nOne of the main strengths of our study is the large sample size including more than 6,700 women with\novarian cancer, making it possible to investigate associations with histologic subtypes of ovarian cancer.\nData were derived from nationwide registers with no risk of selection or recall bias. The registers contain\nvirtually complete and continuously updated data on surgical procedures, diagnoses, and drug use. The\nregister-based design of our study thereby enabled us to ensure that all control women had at least one\nintact ovary and provided us with information on important potential confounding factors such as MHT\nuse and endometriosis.\nOur study also has some limitations. Although all of our cases were histologically veried, we did not\nperform a central pathology review of the ovarian tumors, and there may therefore be some degree of\nmisclassication, especially affecting those cancers diagnosed in the early part of our study period.\nMoreover, we did not have information on tumor grade which precluded us from differentiating between\nlow and high-grade serous carcinomas. Finally, left truncation of prescription data may have led to\nmisclassication of MHT use among those women who initiated MHT before 1995, and although the\nDanish National Patient Register was established earlier (1977), information on hysterectomy and\nendometriosis may be incomplete.\nIt is important to know whether to recommend hysterectomy or not when it comes to the risk of ovarian\ncancer, and due to the shift in ndings over time, new studies are required to clarify this. In our study,\nhysterectomy does not protect against ovarian cancer overall, but a potentially decreased risk is\nobserved in women with endometriosis and in non-users of MHT.\nIn this nationwide, register-based case-control study there was no association between hysterectomy\nand risk of ovarian cancer overall, but the analysis by histologic subtype revealed a reduced risk of clear\ncell ovarian cancer. Data also showed reduced odds for ovarian cancer after hysterectomy in women\nwith endometriosis and in women not using MHT, albeit not statistically signicant. The statistical\nprecision of our results do not allow rm conclusions but combined with ndings from other recent\nstudies, they suggest that hysterectomy may be protective against ovarian cancer in these groups of\nwomen.\nDeclarations\nAuthor contribution\nL.L. Ring: Protocol/project development, data analysis, manuscript writing/editing\nL. Baandrup: Protocol/project development, data analysis, manuscript writing/editing\nM. Gottschau: Protocol/project development, data analysis, manuscript writing/editing\n\nPage 13/15\nC. Dehlendorff: Data collection or management, data analysis, manuscript writing/editing \nL. Mellemkjær: Protocol/project development, data analysis, manuscript writing/editing\nS.K. Kjaer: Protocol/project development, data analysis, manuscript writing/editing\nFunding \nThis work was supported by the Mermaid project [Mermaid 3]. The funding sources had no role in the\ndesign and conduct of the study; collection, management, analysis, and interpretation of the data;\npreparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.\nCompeting Interests \nLene Mellemkjær has an immediate family member employed at Novo Nordisk, and has an immediate\nfamily member who owns stocks in Novo Nordisk. All other authors declare no conicts of interest. \nReferences\n1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer\nStatistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185\nCountries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660\n2. Prat J, D'Angelo E, Espinosa I (2018) Ovarian carcinomas: at least ve different diseases with\ndistinct histological features and molecular genetics. Hum Pathol 80:11–27.\nhttps://doi.org/10.1016/j.humpath.2018.06.018\n3. Madsen C, Baandrup L, Dehlendorff C, Kjaer SK (2015) Tubal ligation and salpingectomy and the risk\nof epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta\nObstet Gynecol Scand 94:86–94. https://doi.org/10.1111/aogs.12516\n4. Rice MS, Murphy MA, Tworoger SS (2012) Tubal ligation, hysterectomy and ovarian cancer: A meta-\nanalysis. J Ovarian Res 5:13. https://doi.org/10.1186/1757-2215-5-13\n5. Huo X, Yao L, Han X, Li W, Liu J, Zhou L, Gou Y, Yang K, Liu H (2019) Hysterectomy and risk of\novarian cancer: a systematic review and meta-analysis. Arch Gynecol Obstet 299:599–607.\nhttps://doi.org/10.1007/s00404-018-5020-1\n. Dixon-Suen SC, Webb PM, Wilson LF, Tuesley K, Stewart LM, Jordan SJ (2019) The Association\nBetween Hysterectomy and Ovarian Cancer Risk: A Population-Based Record-Linkage Study. J Natl\nCancer Inst 111:1097–1103. https://doi.org/10.1093/jnci/djz015\n7. Falconer H, Yin L, Gronberg H, Altman D (2015) Ovarian cancer risk after salpingectomy: a\nnationwide population-based study. J Natl Cancer Inst 107. https://doi.org/10.1093/jnci/dju410\n. Peres LC, Alberg AJ, Bandera EV et al (2017) Premenopausal Hysterectomy and Risk of Ovarian\nCancer in African-American Women. Am J Epidemiol 186:46–53.\nhttps://doi.org/10.1093/aje/kwx055\n\nPage 14/15\n9. Rice MS, Hankinson SE, Tworoger SS (2014) Tubal ligation, hysterectomy, unilateral oophorectomy,\nand risk of ovarian cancer in the Nurses' Health Studies. Fertil Steril 102:192–8e3.\nhttps://doi.org/10.1016/j.fertnstert.2014.03.041\n10. Khoja L, Weber RP, Australian Ovarian Cancer Study G et al (2022) Endometriosis and menopausal\nhormone therapy impact the hysterectomy-ovarian cancer association. Gynecol Oncol 164:195–201.\nhttps://doi.org/10.1016/j.gyno.2021.10.088\n11. Darelius A, Kristjansdottir B, Dahm-Kahler P, Strandell A (2021) Risk of epithelial ovarian cancer Type\nI and II after hysterectomy, salpingectomy and tubal ligation-A nationwide case-control study. Int J\nCancer 149:1544–1552. https://doi.org/10.1002/ijc.33714\n12. Wentzensen N, Poole EM, Trabert B et al (2016) Ovarian Cancer Risk Factors by Histologic Subtype:\nAn Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol 34:2888–2898.\nhttps://doi.org/10.1200/JCO.2016.66.8178\n13. Jordan SJ, Nagle CM, Coory MD, Maresco D, Protani MM, Pandeya NA, Balasubramaniam KD, Webb\nPM (2013) Has the association between hysterectomy and ovarian cancer changed over time? A\nsystematic review and meta-analysis. Eur J Cancer 49:3638–3647.\nhttps://doi.org/10.1016/j.ejca.2013.07.005\n14. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT (2004) Oral contraceptive\nuse, reproductive history, and risk of epithelial ovarian cancer in women with and without\nendometriosis. Am J Obstet Gynecol 19:733–740. https://doi.org/10.1016/j.ajog.2004.03.035\n15. Taylor JA, Burnell M, Ryan A et al (2022) Association of hysterectomy and invasive epithelial ovarian\nand tubal cancer: a cohort study within UKCTOCS. BJOG 129:110–118.\nhttps://doi.org/10.1111/1471-0528.16943\n1. Morch LS, Lokkegaard E, Andreasen AH, Kjaer SK, Lidegaard O (2009) Hormone therapy and ovarian\ncancer. JAMA 302:298–305. https://doi.org/10.1001/jama.2009.1052\n17. Tsilidis KK, Allen NE, Key TJ et al (2011) Menopausal hormone therapy and risk of ovarian cancer in\nthe European prospective investigation into cancer and nutrition. Cancer Causes Control 22:1075–\n1084. https://doi.org/10.1007/s10552-011-9782-z\n1. Million Women Study C (2002) Patterns of use of hormone replacement therapy in one million\nwomen in Britain, 1996–2000. BJOG 109:1319–1330. https://doi.org/10.1016/s1470-\n0328(02)02914-2\n19. Shih IM, Wang Y, Wang TL (2021) The Origin of Ovarian Cancer Species and Precancerous\nLandscape. Am J Pathol 191:26–39. https://doi.org/10.1016/j.ajpath.2020.09.006\n20. Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39(7 Suppl):22–\n25. https://doi.org/10.1177/1403494810387965\n21. Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39(7 Suppl):42–45.\nhttps://doi.org/10.1177/1403494810393562\n22. Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public\nHealth 39(7 Suppl):30–33. https://doi.org/10.1177/1403494811401482\n\nPage 15/15\n23. Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J\nPublic Health 39(7 Suppl):38–41. https://doi.org/10.1177/1403494810394717\n24. WHO Collaborating Centre for Drug Statistics Methofology (2022)\nhttps://www.whocc.no/atc_ddd_index/. Accessed 11 October 2022\n25. Blenstrup LT, Knudsen LB (2011) Danish registers on aspects of reproduction. Scand J Public Health\n39(7 Suppl):79–82. https://doi.org/10.1177/1403494811399957\n2. Kurman RJ, Shih Ie M (2016) The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and\nExpanded. Am J Pathol. https://doi.org/10.1016/j.ajpath.2015.11.011. 186:733 – 47\n27. Gilks CB(2010) Molecular abnormalities in ovarian cancer subtypes other than high-grade serous\ncarcinoma. J Oncol 2010:740968. https://doi.org/10.1155/2010/740968\nSupplementary Files\nThis is a list of supplementary les associated with this preprint. Click to download.\nSupplementaryMaterial.docx","source_license":"CC0","license_restricted":false}